Innoviva Profit Margin 2010-2024 | INVA

Current and historical gross margin, operating margin and net profit margin for Innoviva (INVA) over the last 10 years. Profit margin can be defined as the percentage of revenue that a company retains as income after the deduction of expenses. Innoviva net profit margin as of March 31, 2024 is 58.21%.
Innoviva Annual Profit Margins
Innoviva Quarterly Profit Margins
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $1.045B $0.310B
Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The company's portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance, Inc., is headquartered in South San Francisco, California.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $901.365B 130.27
Novo Nordisk (NVO) Denmark $637.589B 48.99
Johnson & Johnson (JNJ) United States $360.713B 14.33
Merck (MRK) United States $323.591B 58.88
AbbVie (ABBV) United States $300.692B 15.54
AstraZeneca (AZN) United Kingdom $245.685B 21.36
Novartis AG (NVS) Switzerland $228.315B 16.19
Pfizer (PFE) United States $163.878B 20.37
Sanofi (SNY) $130.005B 12.25